Vitamin E

At standard dietary doses or typical multivitamin levels (15-30 IU), most people feel absolutely nothing from vitamin E. It is not a nootropic in any traditional sense -- there is no acute cognitive effect, no mood shift, no perceptible change. This is a background nutrient doing background work in cell membranes, and that work is not something the nervous system reports to conscious awareness.

At higher supplemental doses (400-800 IU), some men report noticeable effects tied to hormonal shifts. The prolactin reduction can produce improved libido, better post-orgasm recovery, and a subtle increase in energy and motivation. These effects are most pronounced in men who had elevated prolactin to begin with. But the same hormonal mechanism that lowers prolactin also lowers estradiol, and this is where vitamin E supplementation can turn ugly. One widely cited Reddit account describes a user on 800 IU daily who developed progressive depression, crushing fatigue, emotional blunting, and what he described as "psychotic outbursts" -- all of which resolved after stopping the supplement and allowing estradiol to recover.

The practical reality is that there is a narrow therapeutic window where vitamin E produces net-positive hormonal effects, and overshooting it creates problems that are worse than whatever you were trying to fix. If you are supplementing above 400 IU for hormonal reasons, monitoring bloodwork is not optional -- it is the only way to know which side of that window you are on.

Alpha-tocopherol is the most potent chain-breaking lipid-soluble antioxidant in biological membranes. It donates a hydrogen atom from its chromanol hydroxyl group to lipid peroxyl radicals, terminating the lipid peroxidation chain reaction. The resulting tocopheroxyl radical is relatively stable and is regenerated by vitamin C (ascorbate) at the membrane-water interface, establishing the vitamin E-vitamin C antioxidant cycle.

Beyond antioxidant function, vitamin E modulates cell signaling: it inhibits protein kinase C (PKC) activity (anti-proliferative), activates protein phosphatase 2A (PP2A), modulates gene expression through pregnane X receptor (PXR) and other nuclear receptors, and influences eicosanoid metabolism. Alpha-tocopherol inhibits 5-lipoxygenase (reducing leukotriene synthesis) while gamma-tocopherol more effectively traps reactive nitrogen species (peroxynitrite).

Tocotrienols, particularly gamma-tocotrienol, have demonstrated neuroprotective properties independent of antioxidant activity, including inhibition of glutamate-induced neuronal death at nanomolar concentrations through regulation of 12-lipoxygenase and phospholipase A2.

Vitamin E was discovered in 1922 by Herbert McLean Evans and Katharine Scott Bishop and first isolated in a pure form by Evans and Gladys Anderson Emerson in 1935 at the University of California, Berkeley. Because the vitamin activity was first identified as a dietary fertility factor in rats, it was given the name "tocopherol" from the Greek words "τόκος" [tókos, birth], and "φέρειν", [phérein, to bear or carry] meaning in sum "to carry a pregnancy," with the ending "-ol" signifying its status as a chemical alcohol. George M. Calhoun, Professor of Greek at the University of California, was credited with helping with the naming process. Erhard Fernholz elucidated its structure in 1938 and shortly afterward the same year, Paul Karrer and his team first synthesized it.

Nearly 50 years after the discovery of vitamin E, an editorial in the Journal of the American Medical Association titled "Vitamin in search of a disease" read in part "...research revealed many of the vitamin's secrets, but no certain therapeutic use and no definite deficiency disease in man." The animal discovery experiments had been a requirement for successful pregnancy, but no benefits were observed for women prone to miscarriage. Evidence for vascular health was characterized as unconvincing. The editorial closed with mention of some preliminary human evidence for protection against hemolytic anemia in young children.

A role for vitamin E in coronary heart disease was first proposed in 1946 by Evan Shute and colleagues. More cardiovascular work from the same research group followed, including a proposal that megadoses of vitamin E could slow down and even reverse the development of atherosclerosis. Subsequent research showed no association between vitamin E supplementation and cardiovascular events such as nonfatal stroke or myocardial infarction, or cardiovascular mortality.

There is a long history of belief that topical application of vitamin E containing oil benefits burn and wound healing. This belief persists even though scientific reviews refuted this claim.

The role of vitamin E in infant nutrition has a long research history. From 1949 onward there were trials with premature infants suggesting that oral alpha-tocopherol was protective against edema, intracranial hemorrhage, hemolytic anemia and retrolental fibroplasia. A more recent review concluded that vitamin E supplementation in preterm infants reduced the risk of intracranial hemorrhage and retinopathy, but noted an increased risk of sepsis.